The Radiopharmaceutical Infrastructure Playbook: Why Telix's FDA Approval for Pixclara Redefines Neuro-Oncology Diagnostics and Theranostics
Dr. Dereck Mush, MD, MBADr. Christian Behrenbruch
Managing Director and Group CEO, Telix Pharmaceuticals
- Industry
- Precision oncology and radiopharmaceuticals
- Based in
- Melbourne, Australia
- Company funding
- Undisclosed
- Region
- Oceania
Healthcare executive and scientist in molecular imaging and oncology.
Co-founded Telix and leads its global radiopharmaceutical portfolio.
Dr. Christian Behrenbruch is a co-founder and the Managing Director and Group CEO of Telix Pharmaceuticals.
More founders in Precision oncology and radiopharmaceuticals
- Kevin Richardson
Telix Pharmaceuticals
Related on The Signal
Dr. Dereck Mush, MD, MBA
Inside TumorSight Risk: What MRI-Based Recurrence Assessment Can and Cannot Tell Clinicians
Dr. Dereck Mush, MD, MBA
The Post-REMS Long-Acting Psychiatric Revolution: How Subcutaneous Copolymer Delivery Unlocks Olanzapine Outpatient Economics
Dr. Dereck Mush, MD, MBA
Inside SimBioSys TumorSight Risk: Bringing Recurrence Assessment Into the MRI Workflow
Dr. Dereck Mush, MD, MBAKeep exploring